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without underlying abdominal pathology. As far as percutaneous drainage is
concerned, it certainly is a reliable procedure by which pus and necrotic debris may
be removed and the abscess cavity washed. Nevertheless I do not believe that it will
be of any help in treating multiple, superficially located abscesses or in the
management of patients with severe sepsis and associated pathology such as in
acute suppurative cholangitis where the obstruction of the biliary tract results in
multiple abscesses scattered throughout both hepatic lobes and severe sepsis occurs
accounting for the high mortality rate.
The most correct therapeutic approach to pyogenic liver abscess requires an
accurate diagnostic work-up aimed at precisely defining size, location and the
number of lesions as well as the type of pathogens involved. In dealing with this
desease, one last point deserves to be mentioned, the basic rule from times long
past, which still holds good: Ubi pus ibi evacuat.
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PROPHYLACTIC SCLEROTHERAPY FOR
OESOPHAGEAL VARICES
ABSTRACT
The Veterans Affairs Cooperative Variceal Sclerotherapy Group. (1991)
Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver
disease. The New England Journal of Medicine; 324: 1779-1784.
Background. Sclerotherapy is an effective treatment for bleeding esophageal varices
in patients with alcoholic liver disease. It has also been suggested that sclerotherapy
might be effective in preventing initial episodes of bleeding and improving survival
among such patients.328 HPB INTERNATIONAL
Methods. We conducted a prospective, randomized trial comparing prophylactic
sclerotherapy and sham therapy in 281 men with alcoholic liver disease who had at
least three variceai channels and no history of variceal bleeding. All the patients
underwent endoscopy; 143 received sclerotherapy, and 138 received sham therapy.
Results. The two patient groups were well matched at entry with respect to the
extent of liver disease and other clinical indexes, except that other medical illnesses
were significantly more common in the sclerotherapy group. The study’s data-
monitoring board terminated the trial 22.5 months after it began because the rate of
mortality from all causes was singificantly higher in the sclerotherapy group (32.2
percent) than in the sham-therapy group (17.4 percent, p 0.004), despite the fact
that the men who received sclerotherapy had significantly fewer episodes of esopha-
geal variceai bleeding. The causes of death varied, and there is no obvious
explanation for the excess mortality in the sclerotherapy group. After the termina-
tion of treatment, the excess mortality rate in the sclerotherapy group promptly
declined. There were 53 episodes of upper gastrointestinal bleeding (including 10
from esophageal varices and 9 from esophageal ulcers) in the sclerotherapy group
and 40 episodes (including 19 from esophageal varices) in the sham-therapy group.
Complications of sclerotherapy were frequent but seldom life-threatening.
Conclusions. For unknown reasons, prophylactic sclerotherapy is associated with
increased mortality among men with moderate-to-severe alcoholic liver disease and
esophageal varices. Sclerotherapy should not be performed until after an initial
episode of bleeding from esophageal varices has occurred. (N.Engl.J.Med., 1991;
324: 1779-1784.)
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Endoscopic sclerotherapy is used to prevent rebleeding from varices that have
previously bled and to stop hemorrhage from actively bleeding esophageal varices.
Elective sclerotherapy in patients who survive the first variceal bleed reduced these
patients long-term rebieeding rates and their long-term mortality13. Emergent
sclerotherapy performed within four hours of admission in patients with actively
bleeding varices significantly decreases the proportion of patients who continue to
bleed twelve hours after admission, and thus, decreases the in-hospital mortality in
one study4. This study could not be confirmed in a later controlled trial5.
Unfortunately, variceal bleeding is the initial presentation for 50% of cirrhotic
patients6, and the mortality rate with the first variceal bleed is 30 to 50% 7.
Therefore, more than ten controlled trials have examined the efficacy of sclerother-
apy in patients with esophageal varices that never bled8-2. These studies of
prophylactic sclerotherapy have reached conflicting conclusions. By using meta-
analysis to determine the efficacy of prophylactic sclerotherapy including all
English-language articles reporting results of randomized controlled trials of
prophylactic sclerotherapy in adults, prophylactic sclerotherapy reduced the 13th
months mortality rate by 11% (95% confidence interval, 4% 19%), which
represents a 41% relative reduction in mortality rate. Across studies, the mortality
rate reductions were positively correlated with the bleeding rate reduction and
negatively correlated with complications rate.HPB INTERNATIONAL 329
On the contrary a recent study of prophylactic sclerotherapy by Gregory et al.,
(being the representative of the Veterans Affairs Cooperative Variceal
Sclerotherapy Groups thus, this study was exclusively performed in Veterans
Administration Hospitals) showed an unexpectedly high mortality rate in the
treated group (32.2%, as compared with 17.4% in the control group). Child’s score
and sclerotherapy were the main predictors of mortality in this study, but the
increased mortality in the sclerotherapy group persisted after an adjustment for
Child’s score and for other medical illnesses. Sclerotherapy was therefore con-
sidered an important factor causing excessive mortality. The authors concluded,
that prophylactic sclerotherapy is dangerous and should not be performed until
after the first episode of variceal bleeding.
I believe that these results are not astonishing and that the reason for the high
mortality after sclerotherapy are not unknown, as stated in the conclusion of the
abstract. Veteran Administration Hospitals from my personal knowledge are not
hospitals with the highest medical and technical standard in the United States. This
may also be true for the doctors and endoscopists. This is the first factor that may
have influenced the final outcome.
Furthermore this study contains two possible additional conflicting factors. First,
more men in the sclerotherapy group than in the control group had medical
illnesses, such as chronic obstructive pulmonary disease, diabetes mellitus, cardiac
disease and cancer. Second, the initial frequency of the sclerotherapy sessions was
high (four treatments in the first month). Major esophageal ulceration is known to
be associated with a high frequency of sclerotherapy sessions2.
Although, sclerotherapy was singled out as an important factor that was asso-
ciated with increased mortality, for a true understanding of these results, more
detailed knowledge about the causes of death is needed. Why were the rates of fatal
liver failure and infection higher in the sclerotherapy group? What kinds of
infection occurred? Were anti-biotics given at the time of sclerotherapy? What
were the ages of the patients who died? Was there any difference in mortality
among the men who continued to abuse alcohol and those who were abstinent?
Although, there were a few episodes of variceal bleeding in the sclerotherapy
group, there were more episodes of other upper gastrointestinal bleeding in this
group, and more such episodes were fatal. Was bleeding from esophageal ulcers,
which occurred only in the sclerotherapy group, an important cause of death? Was
bleeding from stress ulcers, possibly influenced by inadequate sclerotherapy a
second important cause? Was bleeding from esophageal varices after sclerotherapy
a cause of inadequate experience by the endoscopists, thus influencing the negative
outcome of this group?
The study by Gregory et al. contains a clear warning that prophylactic sclerother-
apy may be not beneficial but instead may be associated with increased mortality, at
least in a study population composed of older, actively drinking men with a rather
high incidence of non-hepatic medical illness. Whether this conclusion also holds
for a study population with a high risk of bleeding but an otherwise reasonable
prognosis (CHILD’s grade A and B) and no other important medical illness
remains in our opinion to be proved. Last but not least, prophylactic endoscopic
sclerotherapy has, as described above in the meta-analysis, proved to be useful in
the hand of experts.
Recently our group finished a prospective controlled randomized trial with a
strict selection of patients (20% of all patients with esophageal varices) according to330 HPB INTERNATIONAL
the following factors at risk to bleed: Esophageal varices degrees III and IV
(according to our classification)8, minivarices on top of the varices (so called
"cherry red spots") and an elevated portal pressure, measured by wedged occluded
hepatic or esophageal variceal pressure over 22mmHg. In this study more than one
hundred patients were included. Over a period of three years it could be demon-
strated, that prophylactic endoscopic sclerotherapy in a selected group of patients
with a high risk of bleeding and performed by doctors with endoscopic expertise is
not only able to reduce the frequency of bleeding but also to prolong survival.
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BUDD-CHIARI SYNDROME TRANSPLANT,
MESO-ATRIAL SHUNT OR COMBINED
PORTOCAVAL SHUNT WITH CAVO-ATRIAL SHUNT
ABSTRACT
Orloff, M.J. and Daily, P.O. (1992) Treatment of Budd-Chiari syndrome due to
inferior oena caoa occlusion by combinedportal and oena caval decompression. The
American Journal of Surgery; 163: 137-143.
This study concerns Budd-Chiari syndrome (BCS) caused by occlusion of the
subdiaphragmatic inferior vena cava (IVC). It describes the experimental and
clinical evaluation of the treatment of this disorder by one-stage combined portal and
vena caval decompression with a direct side-to-side portacaval shunt (PCS) and a
caval-atrial shunt (CAS) graft. BCS was produced in rats by gradual occlusion of the
suprahepatic IVC with an ameroid constrictor. When ascites and portal hyperten-
sion were established, 12 control rats survived a sham thoracolaparotomy, 16 rats
survived a mesoatrial shunt, and 16 rats survived combined PCS and CAS graft. All
control rats re-formed ascites and died within 2 months. Nine of 16 rats with
mesoatrial shunt developed graft thrombosis, re-formed ascites, and died within 2
months. In contrast, only 2 of 16 rats that underwent combined PCS and CAS
developed graft thrombosis, re-formed ascites, and died. Liver biopsies showed
reversal of severe pathologic changes in rats with patent grafts. Clinical evaluation of
combined PCS and CAS using a 20-mm ring-reinforced Gore-Tex graft has been
undertaken in five patients with BCS and ascites, hepatosplenomegaly, intense
hepatic congestion on biopsy, and angiography showing occlusion of both the IVC
and hepatic veins. All five patients were alive and well 6 months to 7.5 years
postoperatively with patent grafts, no ascites or need for diuretics, no encephalo-
pathy, normal liver function, and reversal of liver pathology. It is concluded that
combined PCS and CAS create a high-flow shunt that decompresses both the portal
system and IVC, has a low incidence of graft thrombosis, has been consistently
effective in relieving BCS caused by IVC occlusion, and appears to be superior to
mesoatrial shunt.